Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsPRNewsWire • 03/14/24
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024PRNewsWire • 03/07/24
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor ConferencePRNewsWire • 02/23/24
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business ResultsPRNewsWire • 11/06/23
Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023PRNewsWire • 10/30/23
Protalix BioTherapeutics Issues Statement Regarding Security Situation in IsraelPRNewsWire • 10/09/23
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of DirectorsPRNewsWire • 09/12/23
Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferencePRNewsWire • 09/06/23
Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business ResultsPRNewsWire • 08/07/23
Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferencePRNewsWire • 08/01/23
Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023PRNewsWire • 07/31/23
Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry DiseasePRNewsWire • 06/08/23
Protalix BioTherapeutics Stock: FDA Approval For Elfabrio To Drive ProfitabilitySeeking Alpha • 05/30/23
Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare DiseasesPRNewsWire • 05/18/23
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry DiseasePRNewsWire • 05/10/23
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry DiseasePRNewsWire • 05/05/23